New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
09:21 EDTEXASFDA says Exact Sciences colorectal cancer screening tool study met objectives
Exact Sciences' Deep-C study met the primary objectives with respect to both required sensitivity and specificity of the company's Cologuard test compared to colonoscopy, FDA staff wrote in briefing documents ahead of the March 27 meeting of the Molecular and Clinical Advisory Committee Panel. With respect to the secondary objectives, Cologuard sensitivity is higher than FIT for both CRC and AA, FDA staff noted. Cologuard is an in vitro diagnostic device designed to analyze patientsí stool for the presence of colorectal cancer. Reference Link
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
10:00 EDTEXASOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:56 EDTEXASExact Sciences upgraded to Buy from Hold at Lake Street
Lake Street Capital Markets analyst Bruce Jackson upgraded Exact Sciences to Buy and raised his price target for shares to $30 from $27. The company's Q2 report showed better than expected gross margins and the stock's risk/reward is appealing, Jackson tells investors.
July 21, 2015
09:21 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTEXASExact Sciences 7M share Spot Secondary priced at $25.50
Subscribe for More Information
July 20, 2015
19:02 EDTEXASOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTEXASExact Sciences files to sell 7M shares of common stock
The Company intends to use the net proceeds of this offering to fund expansion of Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes. Jefferies LLC and Robert W. Baird & Co. Incorporated are acting as the underwriters for the offering.
09:22 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
05:32 EDTEXASExact Sciences reports Q2 EPS (44c), consensus (45c)
Reports Q2 revenue $8.1M, consensus $7.96M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use